Synairgen plc
('Synairgen' or the 'Company')
Board Change
Southampton, UK - 5 September 2024:
Synairgen plc (LSE: SNG), the respiratory company developing
SNG001, an investigational formulation for inhalation containing
the broad-spectrum antiviral protein interferon beta,
today announces that, following 18 years of
service, Dr. Phillip Monk is stepping down from the Board and will
leave the Company on 31 December 2024.
With Synairgen's resources dedicated
to the clinical development of SNG001, Dr. Marcin Mankowski became
the Company's Chief Medical Officer in 2023 and will continue to
lead the clinical development strategy for SNG001.
The Company looks forward to
announcing further Board changes ahead of hosting its Annual
General Meeting in early October.
Simon Shaw, Chairman of the Board of Synairgen,
said: "On behalf of the Board and
the team at Synairgen, I would like to express my thanks to Phill
for his significant contribution over many years, particularly for
progressing the early-stage clinical development of SNG001. We wish
him the very best for the future."
For
further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051
2800
Cavendish Capital Markets Limited (NOMAD and Joint
Broker)
Geoff Nash, Camilla Hume, Trisyia
Jamaludin (Corporate Finance)
Sunila de Silva (ECM)
Tel: + 44 (0) 20 7220
0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith,
Euan Brown
Tel: + 44 (0) 20 7260
1000
ICR
Consilium (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak,
Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for
Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery and the development of SNG001
(inhaled interferon beta) as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.
Millions of people globally are
hospitalised every year due to viral lung infections and there are
currently no approved antiviral therapies for the majority of these
patients. Synairgen is developing SNG001 to address this
need.
Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see
www.synairgen.com